TransCode Therapeutics's total assets for Q2 2024 were $4.82M, a decrease of -33.82% from the previous quarter. RNAZ total liabilities were $3.50M for the fiscal quarter, a 29.42% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.